Skip to main content Skip to footer
Nighthawk Biosciences, Inc.
  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
    • Biothreat Advisory Board
  • Ecosystem
    • Overview
    • Subsidiaries
  • Products
    • Anthim
    • Publications
  • Investors & News
    • Overview
    • News & Events
      • Overview
      • Press Releases
      • IR Calendar
      • Email Alerts
    • Company Info
      • Overview
      • Management Team
      • Presentations
      • Contacts
      • FAQ
    • Financial Info
      • Overview
      • Financial Results
      • Income Statement
      • Balance Sheet
      • Cash Flow
    • Stock Data
      • Quote
      • Charts
      • Historical Data
      • Analyst Coverage
    • SEC Filings
      • Overview
      • All SEC Filings
      • Annual Reports
      • Quarterly Reports
      • Section 16 Filings
    • Governance
      • Overview
      • Board of Directors
      • Board Committees
      • Governance Documents
    • Corporate Presentation
  • Careers
  • Contact

Press Releases

Investors & News

Investors & News

  • Overview
  • News & Events
    • Overview
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Company Info
    • Overview
    • Management Team
    • Presentations
    • Contacts
    • FAQ
  • Financial Info
    • Overview
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Quote
    • Charts
    • Historical Data
    • Analyst Coverage
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
  • Corporate Presentation
  • News & Events

  • Overview
  • Press Releases
  • IR Calendar
  • Email Alerts
Nov 14, 2022 4:01pm EST

NightHawk Biosciences Provides Third Quarter 2022 Business Update

Oct 21, 2022 8:00am EDT

Nighthawk Biosciences’ Scorpion Subsidiary Announces Grand Opening of its San Antonio Facility

Aug 23, 2022 7:30am EDT

NightHawk Biosciences Announces Buildout of Advanced Biosafety Level 2 (BSL-2) Laboratory

Aug 10, 2022 4:05pm EDT

NightHawk Biosciences Provides Second Quarter 2022 Business Update

Jun 13, 2022 8:00am EDT

NightHawk Biosciences Appoints Stephan Kutzer, Ph.D. as Interim Chief Executive Officer of Scorpion Biological Services

May 16, 2022 4:44pm EDT

NightHawk Biosciences Provides First Quarter 2022 Business Update

May 10, 2022 8:00am EDT

NightHawk Biosciences to Present at the 4th Annual Treg Directed Therapies Summit on PTX-35

May 03, 2022 7:00am EDT

Heat Biologics Completes Name Change to NightHawk Biosciences; Trading to Commence Under “NHWK” Effective at the Market Open Today

Apr 27, 2022 8:00am EDT

Heat Biologics (NightHawk Biosciences) Announces that its Elusys Therapeutics Subsidiary has Executed a Contract to Deliver ANTHIM® to the Canadian Government

Apr 20, 2022 8:00am EDT

Heat Biologics (“NightHawk Biosciences”) Completes Acquisition of Elusys Therapeutics

  • Page 1
  • Page 2
  • Page 3
  • Page 4
  • Page 5
  • Page 6
  • Page 7
  • Page 8
  • Page 9
  • Page 10
  • …
  • Page 29
  • Next Pagearrow_forward
rss_feed News RSS
NightHawk Biosciences

OUR ECOSYSTEM

SkunkWorx Bio
Elusys Therapeutics Inc.
Scorpius Biological Services
  • Email Alerts
  • Contacts
  • RSS News Feed
©2023 Nighthawk Biosciences, Inc. All Rights Reserved.
Privacy Policy Disclaimer Sitemap
  • Visit us on LinkedIn
  • Visit us on Twitter
  • Visit us on YouTube
  • Visit us on Facebook

This website uses cookies.

We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.